"Navigating the Modern News Zoo so you don't have to."
Tuesday, April 22, 2025
Some lung cancer patients may experience durable disease control even after discontinuing immunotherapy
A subset of patients with non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhibitor (ICI) therapy due to immune-related adverse events (irAEs) continued to experience long-term disease control, according to findings published in Clinical Cancer Research.
đ Full Story
Black Attorney vs White Cop đ€Ł
- Yes, There Is a Left-Wing Violence Problem in This Country - Becket Adams
- Unraveling the Mysteries of Black Holes and Entropy - Arya Chandran
- Trip to Florida gas station turns into $25 million lottery win
- How to Invest in Silver
- Worldâs Best Investment Banks 2025: Global And Country Winners - Thomas Monteiro
- The Innovative Approach to Track Small Space Debris - Arya Chandran
Android Will Help You Pass Exam!
- Trump Needs to See âEnthusiasmâ from Russia, Ukraine to End War if U.S. Is to Remain in Peace Talks - MeighTimbol
- Trump admin science director says American tech can 'manipulate time and space'
- Hospitalizations For Ozempic Side Effects Are RareâBut When Should You Go to the ER? - Simon Spichak
- ChatGPT Experiences Outage Amid OpenAI's Internal Turmoil - Michael Terry
- Basal cell carcinoma's low immunogenicity linked to suppression of antigen presentation from its cell of origin
- Conservative Students Must Save Higher Education from Itself - Jeb Allen
